Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 13/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22512575 | 0.95 | HSD17B3 (0.48) | NOTUMHSD17B3CYP2D6CYP2C9 | |
| SCHEMBL24408083 | 0.91 | TOP2A (0.38) | NOTUMHSD17B3CYP2C9TOP2AMAP3K5 | |
| SCHEMBL23280914 | 0.89 | KDM4E (0.48) | NOTUMHSD17B3CYP2C9TOP2AMAP3K5 | |
| SCHEMBL19604359 | 0.89 | KMT2A (0.39) | NOTUMHSD17B3CYP2D6CYP2C9TOP2A | |
| SCHEMBL23961928 | 0.88 | TSHR (0.39) | NOTUMHSD17B3CYP2C9 | |
| SCHEMBL21396376 | 0.88 | SMN1; SMN2 (0.37) | NOTUMCYP2C9TOP2AMAP3K5 | |
| SCHEMBL27422296 | 0.87 | KDM4E (0.36) | NOTUMCYP2C9TOP2AMAP3K5 | |
| SCHEMBL20758286 | 0.86 | ALDH1A1 (0.39) | NOTUMHSD17B3CYP2C9TOP2AMAP3K5 | |
| SCHEMBL16204540 | 0.85 | NOTUM (0.48) | NOTUMHSD17B3 | |
| SCHEMBL23961925 | 0.85 | TSHR (0.38) | NOTUMCYP2C9TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073622-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20230399356-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-14 | — | — | US | disclosed |
| EP-4279089-A1 | DISACCHARIDE LINKER, DISACCHARIDE-SMALL MOLECULE DRUG CONJUGATE AND SUGAR CHAIN FIXED-POINT ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023173026-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | SORRENTO THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2022271818-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | ENTRADA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-3960767-A2 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | Novartis AG (CH) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399356-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | NOTUM 4371/4885HSD17B3 4131/4885CYP2D6 1662/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | NOTUM 3088/4885HSD17B3 4113/4885CYP2D6 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.